Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

CardioVascular BioTherapeutics presents phase II data on CVBT-141B

Jan. 5, 2011

New target identified for treatment of psoriasis-associated skin inflammation

Jan. 5, 2011

BL-5010 is efficacious in nonsurgical removal of skin lesions in phase I/II trial

Jan. 3, 2011

Shionogi and AnGes to codevelop NFkB decoy oligo

Dec. 29, 2010

Isotechnika and Paladin seek Canadian marketing approval for Voclera

Dec. 22, 2010

Provectus begins phase IIc trial of PH-10 in psoriasis

Dec. 17, 2010

Phase IIa results reported for Creabilis' CT-327 in atopic dermatitis

Dec. 16, 2010

Capstone releases phase IIa data on AZX-100 for treatment of keloid and surgical scarring

Dec. 14, 2010

CardioVascular BioTherapeutics licenses phase II data for FGF-1

Dec. 3, 2010

Elorac's naloxone lotion receives FDA orphan drug status in CTCL-associated pruritus

Dec. 3, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...